5 research outputs found
Application of Free Energy Perturbation for the Design of BACE1 Inhibitors
Novel
spiroaminodihydropyrroles probing for optimized interactions
at the P3 pocket of Ī²-secretase 1 (BACE1) were designed with
the use of free energy perturbation (FEP) calculations. The resulting
molecules showed pIC<sub>50</sub> potencies in enzymatic BACE1 inhibition
assays ranging from approximately 5 to 7. Good correlation was observed
between the predicted activity from the FEP calculations and experimental
activity. Simulations run with a default 5 ns approach delivered a
mean unsigned error (MUE) between prediction and experiment of 0.58
and 0.91 kcal/mol for retrospective and prospective applications,
respectively. With longer simulations of 10 and 20 ns, the MUE was
in both cases 0.57 kcal/mol for the retrospective application, and
0.69 and 0.59 kcal/mol for the prospective application. Other considerations
that impact the quality of the calculations are discussed. This work
provides an example of the value of FEP as a computational tool for
drug discovery
Application of Free Energy Perturbation for the Design of BACE1 Inhibitors
Novel
spiroaminodihydropyrroles probing for optimized interactions
at the P3 pocket of Ī²-secretase 1 (BACE1) were designed with
the use of free energy perturbation (FEP) calculations. The resulting
molecules showed pIC<sub>50</sub> potencies in enzymatic BACE1 inhibition
assays ranging from approximately 5 to 7. Good correlation was observed
between the predicted activity from the FEP calculations and experimental
activity. Simulations run with a default 5 ns approach delivered a
mean unsigned error (MUE) between prediction and experiment of 0.58
and 0.91 kcal/mol for retrospective and prospective applications,
respectively. With longer simulations of 10 and 20 ns, the MUE was
in both cases 0.57 kcal/mol for the retrospective application, and
0.69 and 0.59 kcal/mol for the prospective application. Other considerations
that impact the quality of the calculations are discussed. This work
provides an example of the value of FEP as a computational tool for
drug discovery
Continuous Flow Ī±āArylation of <i>N</i>,<i>N</i>āDialkylhydrazones under Visible-Light Photoredox Catalysis
The first direct
Ī±-arylation of aldehyde-derived <i>N</i>,<i>N</i>-dialkylhydrazones with electron deficient
aryl and heteroaryl cyanides under visible-light photoredox catalysis
has been developed. Structurally complex Ī±,Ī±ā²-diaryl-<i>N</i>,<i>N</i>-cycloalkylhydrazones were obtained
in moderate yields by repetition of the direct arylation protocol.
A continuous-flow procedure for the preparation of Ī±-aryl-<i>N</i>,<i>N</i>-dialkylhydrazones on a multigram scale
has also been established
Acylguanidine Beta Secretase 1 Inhibitors: A Combined Experimental and Free Energy Perturbation Study
A series
of acylguanidine beta secretase 1 (BACE1) inhibitors with
modified scaffold and P3 pocket substituent was synthesized and studied
with free energy perturbation (FEP) calculations. The resulting molecules
showed potencies in enzymatic BACE1 inhibition assays up to 1 nM.
The correlation between the predicted activity from the FEP calculations
and the experimental activity was good for the P3 pocket substituents.
The average mean unsigned error (MUE) between prediction and experiment
was 0.68 Ā± 0.17 kcal/mol for the default 5 ns lambda window simulation
time improving to 0.35 Ā± 0.13 kcal/mol for 40 ns. FEP calculations
for the P2ā² pocket substituents on the same acylguanidine scaffold
also showed good agreement with experiment and the results remained
stable with repeated simulations and increased simulation time. It
proved more difficult to use FEP calculations to study the scaffold
modification from increasing 5 to 6 and 7 membered-rings. Although
prediction and experiment were in agreement for short 2 ns simulations,
as the simulation time increased the results diverged. This was improved
by the use of a newly developed āCore Hopping FEP+ā
approach, which also showed improved stability in repeat calculations.
The origins of these differences along with the value of repeat and
longer simulation times are discussed. This work provides a further
example of the use of FEP as a computational tool for molecular design
Identification of a Novel Orally Bioavailable Phosphodiesterase 10A (PDE10A) Inhibitor with Efficacy in Animal Models of Schizophrenia.
We
report the continuation of a focused medicinal chemistry program aimed
to further optimize a series of imidazoĀ[1,2-<i>a</i>]Āpyrazines
as a novel class of potent and selective phosphodiesterase 10A (PDE10A)
inhibitors. In vitro and in vivo pharmacokinetic and pharmacodynamic
evaluation allowed the selection of compound <b>25a</b> for
its assessment in preclinical models of psychosis. The evolution of
our medicinal chemistry program, structureāactivity relationship
(SAR) analysis, as well as a detailed pharmacological profile for
optimized lead <b>25a</b> are described